Cargando…

An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia

SIMPLE SUMMARY: B cell acute lymphoblastic leukemia (B-ALL) is a common blood cancer characterized by proliferating and accumulating malignant, immature B cells within the body. Despite recent successes in B-ALL therapy, there is still a need for new therapeutic options. In the present study, we rep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riegg, Fabian, Lutz, Martina S., Schmied, Bastian J., Heitmann, Jonas S., Queudeville, Manon, Lang, Peter, Jung, Gundram, Salih, Helmut R., Märklin, Melanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036612/ https://www.ncbi.nlm.nih.gov/pubmed/33915811 http://dx.doi.org/10.3390/cancers13071632

Ejemplares similares

Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody
por: Schmied, Bastian J., et al.
Publicado: (2019)

An Fc-Optimized CD133 Antibody for Induction of Natural Killer Cell Reactivity Against Colorectal Cancer
por: Schmied, Bastian J., et al.
Publicado: (2019)

B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma
por: Hagelstein, Ilona, et al.
Publicado: (2022)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
por: Lutz, Martina Svenja, et al.
Publicado: (2022)

Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
por: Märklin, Melanie, et al.
Publicado: (2019)

Identification of CD318 (CDCP1) as novel prognostic marker in AML
por: Heitmann, Jonas S., et al.
Publicado: (2020)

Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab
por: Haen, Sebastian P., et al.
Publicado: (2016)

CD105 (Endoglin) as negative prognostic factor in AML
por: Kauer, Joseph, et al.
Publicado: (2019)

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
por: Kauer, Joseph, et al.
Publicado: (2022)

Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
por: Heitmann, Jonas S., et al.
Publicado: (2021)

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
por: Kauer, Joseph, et al.
Publicado: (2020)

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
por: Heitmann, Jonas S., et al.
Publicado: (2023)

Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab
por: Queudeville, Manon, et al.
Publicado: (2017)

Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas
por: Hagelstein, Ilona, et al.
Publicado: (2021)

DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis
por: Chashchina, Anna, et al.
Publicado: (2021)

CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies
por: Kauer, Joseph, et al.
Publicado: (2021)

Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia
por: Marconato, Maddalena, et al.
Publicado: (2022)

Identification of CD105 (endoglin) as novel risk marker in CLL
por: Greiner, Sarah M., et al.
Publicado: (2022)

Blinatumomab in Pediatric Acute Lymphoblastic Leukemia—From Salvage to First Line Therapy (A Systematic Review)
por: Queudeville, Manon, et al.
Publicado: (2021)

IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer
por: Lutz, Martina S., et al.
Publicado: (2023)

Characterization and identification of leukemia initiating cells in pediatric acute lymphoblastic leukemia
por: Trentin, Luca, et al.
Publicado: (2014)

Therapeutic Silencing of BCL-2 Using NK Cell-Derived Exosomes as a Novel Therapeutic Approach in Breast Cancer
por: Kaban, Kübra, et al.
Publicado: (2021)

Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma
por: Heitmann, Jonas S, et al.
Publicado: (2020)

Th1 cytokines in pediatric acute lymphoblastic leukemia
por: Schober, Sarah, et al.
Publicado: (2023)

NK Cell-Fc Receptors Advance Tumor Immunotherapy
por: Sanseviero, Emilio
Publicado: (2019)

Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course
por: Clar, Kim L., et al.
Publicado: (2021)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
por: Mehta, Naveen K, et al.
Publicado: (2022)

Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity()
por: Rothfelder, Kathrin, et al.
Publicado: (2018)

The challenges of translation
por: Salih, Helmut R, et al.
Publicado: (2019)

Immunoprofiling of 4-1BB Expression Predicts Outcome in Chronic Lymphocytic Leukemia (CLL)
por: Kaban, Kübra, et al.
Publicado: (2021)

How to outsmart NK cell tolerance
por: Terszowski, Grzegorz, et al.
Publicado: (2015)

Expression and function of FcγRII on NK cells in rhesus macaques
por: He, X, et al.
Publicado: (2012)

Differential Regulation of NK Cell Receptors in Acute Lymphoblastic Leukemia
por: Lee, Le Jie, et al.
Publicado: (2022)

FcRγ Gene Editing Reprograms Conventional NK Cells to Display Key Features of Adaptive Human NK Cells
por: Liu, Weiru, et al.
Publicado: (2020)

Overcoming apoptosis resistance in high risk acute lymphoblastic leukemia by SMAC mimetics in a preclinical ALL xenograft model in vivo
por: Schirmer, Melanie, et al.
Publicado: (2014)

T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals
por: Bilich, Tatjana, et al.
Publicado: (2021)

NK Cells as Possible Prognostic Factor in Childhood Acute Lymphoblastic Leukemia
por: Mizia-Malarz, Agnieszka, et al.
Publicado: (2019)

Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia
por: Märklin, Melanie, et al.
Publicado: (2020)

An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
por: Zekri, Latifa, et al.
Publicado: (2020)

Single-cell quantification of functional outcomes of CD16 ligation in NK cells by Fc-engineered antibodies
por: Romain, Gabrielle, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_eu3rt2ud2e2t58o1ms5tsghgsj